Strides Pharma Science Limited

This article has multiple issues. Please help or discuss these issues on the talk page. (Learn how and when to remove these template messages) A major contributor to this article appears to have a close connection with its subject. It may require cleanup to comply with Wikipedia's content policies, particularly neutral point of view. Please discuss further on the talk page. (June 2019) (Learn how and when to remove this template message) This article contains content that is written like an advertisement. Please help by removing promotional content and inappropriate external links, and by adding encyclopedic content written from a neutral point of view. (June 2019) (Learn how and when to remove this template message) This article relies too much on references to primary sources. Please improve this by adding secondary or tertiary sources. (October 2014) (Learn how and when to remove this template message) (Learn how and when to remove this template message)

Strides Pharma Science Limited

Strides Headquarters in Bengaluru, India
Formerly	Strides Shasun Limited
Type	MNC (several JVs, and subsidiaries)
Traded as	NSE: STAR BSE: 532531
Industry	Pharmaceutical
Founded	1990
Founder	Arun Kumar
Headquarters	Strides House, Bilekahalli, Bannerghatta Road, Bangalore, India
Key people	Arun Kumar, Founder and Chairman of the Board Dr. R. Ananthanarayanan, CEO & Managing Director Badree Komandur, Executive Director & Group CFO Christoph Funke - Chief Operations Officer
Products	General Tablets, Hard Gelatin Capsules, Soft Gelatin Capsules, Sachets, Semi Solids, Ointments, Creams
Revenue	₹2,805 crore (US$370 million) (FY 2020)[1]
Operating income	₹239 crore (US$32 million) (FY 2020)[1]
Net income	₹54 crore (US$7.2 million) (FY 2020)[1]
Number of employees	3500+
Website	www.strides.com

Strides Pharma Science Limited, incorporated in 1990, is a pharmaceutical company headquartered in Bangalore, India. The company is listed on the Bombay Stock Exchange and National Stock Exchange of India Limited. Strides is engaged in the development, manufacture, and marketing of pharmaceutical products for regulated and emerging markets. It has seven manufacturing facilities including four US Food and Drug Administration approved facilities. Strides also has in-house R&D infrastructure in Bengaluru, India.

History[]

Strides was founded in 1990 by Arun Kumar as “Strides Pharmaceuticals Private Limited”.^[2] Over the years, it has grown through numerous strategic moves to attain its position of today.

Some of the key milestones and phases for Strides areː

1990-94 - Incorporation and Initial Phase

• Initial foray as an emerging market FDF company with third party manufacturing

1994-03 - Foray into Specialised manufacturing

• Commenced manufacturing of sterile’s, soft-gel capsules, ARVs and anti-TB drugs

2004-08 - Front-end acquisitions and R&D pipeline

• Acquisition of front-end platforms in SE Asia, Australia and India

2008-12 - Regulated markets focus

• Partnerships with global pharmaceutical companies for regulated markets

2012-13 - Value creation in Strides 1.0

- Sale of Branded generics business in Australia (Ascent)

• Sale to Watson for A$375 million in 2012

-Sale of Specialty injectables(Operated as Agila)

• Sale to Mylan for enterprise value of up to US$1.75 billion in 2013
• Distributed dividends @ INR 605/share in FY14 and FY15; Total pay-out of US$655 million

2014- Current - Strides 2.0 with B2C Focus

Business segments[]

Regulated markets[]

• Front-end presence across the US , Europe, Canada and South Africa.
• Five facilities [Four USFDA approved] in India, Europe and Singapore.

Emerging markets[]

• Front-end focused markets of Africa, Southeast Asia with a portfolio of branded generics
• Two manufacturing facilities dedicated for emerging market operations – One facility at Universal Corporation, Kenya and one manufacturing facility in Bengaluru, India
• Catering to donor-funded programmes using the local facility in Africa.

Key markets of operations[]

North America[]

Strides Pharma Inc. is front-end company for Strides's operations in the US.

Strides re-entered the US market in 2015 post the divestment of its Specialty injectables franchisee- Agila to Mylan Inc. Its focus is mainly on niche, low volume, low competition, high technology barrier products built around Modified Releases, soft-gel capsules (SGCs), topicals and liquids. In the Consumer Healthcare space, Strides operate both in Brands as well as Private Labels and its key brands include JointFlex, Vanquish, Pediacare and Fergon. At the end of July 2018, Strides had a portfolio of 100+ filed ANDAs ANDAs with 65+ product approvals.

Africa[]

Strides business activities in this continent are driven by the philosophy of “In Africa for Africa” which it bolstered with the acquisition of a WHO-approved facility under Universal Corporations in Kenya. Strides has a significant sales footprint in 40+ African countries with a robust medical field force in Africa that helps extend reach to 30,000 doctors.

UK[]

Strides operates in the UK through its step down wholly owned subsidiary Strides Pharma UK Ltd, who have been reliably supplying high-quality generics to Tier 1 & Tier 2 wholesalers in the retail sector as well as the National Health Service through tenders.

Germany, Austria and Switzerland (DACH region)[]

Strides Pharma Global Pte Ltd has acquired a majority stake in Fairmed Healthcare AG, a Switzerland based company with a portfolio of high‐quality generic products encompassing prescription and over‐the‐counter drugs across several therapeutic segments. Fairmed Healthcare has built a strong franchise of supplying high‐quality Rx and OTC products in key European markets and the acquisition will augment Strides’ footprint in continental Europe with a direct presence in the German speaking markets of Germany, Austria and Switzerland collectively called as DACH region. Strides’ vast international product portfolio and Fairmed Healthcare’s market access in the DACH region is a highly complementary combination to pivot an extensive growth in the coming years. The business will incrementally have access to Strides’ already approved product portfolio for the markets Fairmed operates in with supplies from several of its EU approved facilities.

Institutional business[]

Strides is an approved supplier to institutionally funded aid projects and Global Procurement Agencies like USAID, Global Fund, PEPFAR (The US President's Emergency Plan for AIDS Relief), UNICEF, WHO, Pan American Health Organization (PAHO), United Nations Development Program (UNDP), Population Services International (PSI), Chemeonics, PFSCM, amongst others. Its products are supplied to disease-prone regions in Africa, Asia and Latin America with distribution to several areas.

Manufacturing facilities in India and overseas[]

Strides has a global manufacturing footprint with seven production units spread across three continents. Five of its manufacturing facilities cater to regulated markets have key regulatory approvals including USFDA, UK MHRA, TGA, PMDA ANVISA, WHO. The Company also own two dedicated production facilities for the emerging markets at Kenya and Bengaluru, India.

Research and development in Bengaluru, India[]

Strides is led and driven by its expertise in Research and Development, visible through its success in creating niche and differentiated products portfolio. Its Global Formulation R&D centre at Bangalore drives high value product delivery via latest technology platforms.

References[]

External links[]

• Official website
• https://www.thehindubusinessline.com/companies/strides-shasun-seeks-shareholders-nod-to-change-name-to-strides-pharma-science/article24021359.ece
• https://www.business-standard.com/article/companies/strides-pharma-gets-us-fda-approval-for-hypokalemia-treatment-drug-118090500840_1.html
• http://www.thehindu.com/business/Industry/shasun-pharmaceuticals-to-merge-with-strides-arcolab/article6458529.ece
• http://businesstoday.intoday.in/story/best-indian-ceos-2014-arun-kumar-strides-arcolab-pharma/1/212734.html